Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy

• Eyal Asor ,

  Contributed equally to this work with: Eyal Asor, Michael Y. Stav

  Affiliations B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, Institute of Pathology, Rambam Health Care Campus, Haifa, Israel

  ⨯
• Michael Y. Stav ,

  Contributed equally to this work with: Eyal Asor, Michael Y. Stav

  Affiliation Institute of Pathology, Rambam Health Care Campus, Haifa, Israel

  ⨯
• Einav Simon,

  Affiliation B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

  ⨯
• Ibrahim Fahoum,

  Affiliation Institute of Pathology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

  ⨯
• Edmond Sabo,

  Affiliations B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, Institute of Pathology, Rambam Health Care Campus, Haifa, Israel

  ⨯
• Ofer Ben-Izhak,

  Affiliations B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel, Institute of Pathology, Rambam Health Care Campus, Haifa, Israel

  ⨯
• Dov Hershkovitz

  * E-mail: dovh@tlvmc.gov.il

  Affiliations Institute of Pathology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

  ⨯